AbbVie Inc. (ABBV) Management Presents at JPMorgan 40th Annual Healthcare Conference (Transcript)Seeking Alpha • 01/12/22
AbbVie Confirms Guidance of Greater Than $15 Billion in Combined Risk-Adjusted Sales for Rinvoq and Skyrizi in 2025PRNewsWire • 01/11/22
AbbVie: Does Record Price Change Our Bull Thesis? No According To Buffett's RuleSeeking Alpha • 01/11/22
AbbVie Submits Applications for Upadacitinib (RINVOQ®) in Non-Radiographic Axial Spondyloarthritis to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)PRNewsWire • 01/07/22
AbbVie Announces U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for Previously Treated Non-Small Cell Lung CancerPRNewsWire • 01/04/22